John Bradley Sorenson, Executive Vice President of Global Operations at Boston Scientific Corp (NYSE:BSX), recently executed a significant stock transaction. On November 8, Sorenson sold 30,580 shares of common stock, generating a total of approximately $2.68 million. The shares were sold at a weighted average price of $87.66, with individual transaction prices ranging from $87.32 to $87.94.
In a related transaction, Sorenson acquired 17,362 shares through the exercise of stock options at a price of $24.55 per share. This acquisition was part of a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024. Following these transactions, Sorenson holds 39,706 shares of Boston Scientific common stock.
These transactions reflect Sorenson's ongoing management of his equity stake in the company, which specializes in surgical and medical instruments.
In other recent news, Boston Scientific Corporation (NYSE:BSX) has resumed its AVANT GUARD clinical trial, focusing on drug-naïve patients with persistent atrial fibrillation. The company has also announced plans to acquire Cortex, a firm known for its unique cardiac mapping system, OptiMap. This acquisition, perceived positively by analysts at TD (TSX:TD) Cowen, is expected to enhance Boston Scientific's electrophysiology portfolio.
Boston Scientific reported significant growth in its cardiology business, with a 27% increase in the U.S. and 18% internationally. This growth is attributed to strong performances in the ICTx and EP business sectors, and the WATCHMAN franchise. Additionally, the company has received recent product approvals, including the FARAVIEW mapping software and FARAWAVE NAV catheter.
Despite the ACURATE IDE trial not meeting its primary endpoint, the ACURATE platform demonstrated a 20% revenue growth in EMEA, surpassing $200 million. Boston Scientific is also investing in mitral and tricuspid therapies, aiming to double the global drug-coated balloon business by 2025. These are among the recent developments in the company's ongoing commitment to innovation and growth in the cardiology market.
InvestingPro Insights
The recent stock transactions by John Bradley Sorenson, Executive Vice President of Global Operations at Boston Scientific Corp (NYSE:BSX), align with the company's strong market performance and financial health. According to InvestingPro data, Boston Scientific's stock has shown impressive returns, with a 72.07% price total return over the past year and a 53.47% return year-to-date. This robust performance is reflected in the stock trading near its 52-week high, with the current price at 99.67% of that peak.
Boston Scientific's financial metrics further support its strong market position. The company's revenue growth of 15.66% over the last twelve months and a quarterly growth of 19.34% in Q3 2024 indicate solid business expansion. Additionally, the company maintains a healthy gross profit margin of 68.74%, suggesting efficient operations and pricing power in the Healthcare Equipment & Supplies industry.
InvestingPro Tips highlight that Boston Scientific is expected to see net income growth this year, and 20 analysts have revised their earnings upwards for the upcoming period. These positive indicators may explain why insiders like Sorenson are managing their equity positions, potentially balancing portfolio diversification with confidence in the company's future prospects.
For investors seeking more comprehensive analysis, InvestingPro offers 18 additional tips for Boston Scientific, providing deeper insights into the company's valuation, growth prospects, and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.